Update
$Windtree Therapeutics (WINT.US)$ Reuters· 1 min ago
Windtree Therapeutics Inc: Istaroxime Significantly Improved Primary Endpoint of Systolic Blood Pressure Profile Over Six Hours
Windtree Therapeutics Inc: Istaroxime Significantly Improved Primary Endpoint of Systolic Blood Pressure Profile Over Six Hours
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
